Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more
Fate Therapeutics Inc (FATE) - Total Liabilities
Latest total liabilities as of September 2025: $109.61 Million USD
Based on the latest financial reports, Fate Therapeutics Inc (FATE) has total liabilities worth $109.61 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fate Therapeutics Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Fate Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Fate Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Fate Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ACT Energy Technologies Ltd.
TO:ACX
|
Canada | CA$208.70 Million |
|
Domo Inc
NASDAQ:DOMO
|
USA | $393.54 Million |
|
Attica Holdings S.A.
AT:ATTICA
|
Greece | €855.40 Million |
|
ProQR Therapeutics BV
NASDAQ:PRQR
|
USA | $67.28 Million |
|
MacroGenics Inc
NASDAQ:MGNX
|
USA | $203.76 Million |
|
Maider Medical Industry Equipment Co Ltd
SHG:688310
|
China | CN¥357.60 Million |
|
Motorpoint Group plc
PINK:MTPTF
|
USA | $166.70 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Fate Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fate Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fate Therapeutics Inc (2011–2024)
The table below shows the annual total liabilities of Fate Therapeutics Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $121.97 Million | -11.49% |
| 2023-12-31 | $137.80 Million | -37.82% |
| 2022-12-31 | $221.62 Million | -8.65% |
| 2021-12-31 | $242.62 Million | +1.93% |
| 2020-12-31 | $238.01 Million | +313.80% |
| 2019-12-31 | $57.52 Million | +9.43% |
| 2018-12-31 | $52.56 Million | +87.04% |
| 2017-12-31 | $28.10 Million | +28.36% |
| 2016-12-31 | $21.89 Million | -26.82% |
| 2015-12-31 | $29.92 Million | +30.86% |
| 2014-12-31 | $22.86 Million | +382.87% |
| 2013-12-31 | $4.74 Million | -92.59% |
| 2012-12-31 | $63.90 Million | +9.17% |
| 2011-12-31 | $58.53 Million | -- |